Frontiers of Science: Prof. Jason Sheltzer

Event Details

Frontiers of Science: Prof. Jason Sheltzer

April 27th at 12:00
on-site event
Pha1 auditorium, Pharmacity
Spring 2023 program

Prof. Jason Sheltzer, Yale School of Medicine, USA
Mischaracterized anti-cancer agents and their true targets
Host: Jukka Westermarck (jukwes@utu.fi)

Coffee and sandwich served at 11:45

 

Six students and early-career postdocs are welcome to have a lunch in restaurant Mauno and discuss with Prof. Sheltzer after the seminar. This is a great possibility to learn hosting skills in friendly environment and create connections for future. Every student are welcome to join, in spite of which research group they belong to. BioCity Turku will offer the lunch.

If you got interested, please send an email to biocityturku@bioscience.fi

 

The Sheltzer Lab studies the genetic changes that drive cancer progression and cause developmental disabilities. The group is particularly interested in a condition called aneuploidy – a state in which cells gain or lose whole chromosomes. Aneuploidy is found in more than 90% of human tumors and is the most common cause of miscarriage and intellectual disability, but its effects on cell physiology are poorly understood. We apply a variety of complementary technologies, including chromosome engineering, CRISPR/Cas9 mutagenesis, and single cell sequencing, in order to develop new ways to model aneuploidy and to better understand its cellular and organismal consequences. The genetic alterations that occur during tumorigenesis re-wire the underlying architecture of cancer cells and create certain cancer “dependencies”: genes and pathways that are required for cancer cell growth but that are dispensable in normal tissue. Drugs that inhibit the function of a cancer dependency can serve as potent therapeutic agents. Using CRISPR/Cas9, the Sheltzer Lab is working to identify novel cancer dependencies, and to improve the characterization of the drugs that target them.

 

Selected publications

Schukken KM, Sheltzer JM. 2022. Extensive protein dosage compensation in aneuploid human cancers. Genome Res. 32:1254-1270

Smith JC, Sheltzer JM. 2022. Genome-wide identification and analysis of prognostic features in human cancers. Cell Rep. 38:110569

Chen WC, Zhou J, Sheltzer JM, Kinney JB, McCandlish DM. 2021. Field-theoretic density estimation for biological sequence space with applications to 5′ splice site diversity and aneuploidy in cancer. Proc Natl Acad Sci U S A. 118:e2025782118

Vasudevan A, Schukken KM, Sausville EL, Girish V, Adebambo OA, Sheltzer JM. 2021. Aneuploidy as a promoter and suppressor of malignant growth. Nat Rev Cancer. 21:89-103

Lin A, Sheltzer JM. 2020. Discovering and validating cancer genetic dependencies: approaches and pitfalls. Nat Rev Genet. 21:671-682

Smith JC, Sheltzer JM. 2018. Systematic identification of mutations and copy number alterations associated with cancer patient prognosis. Elife. 7:e39217

 

General information

  • You can download all spring 2023 FoS-seminars in your calendar from here: https://seafile.utu.fi/d/4a0b831f23ef420786b0/
  • Registration is not needed for the on-site seminars
  • Participation list is circulated in the audience
  • If you are a student and later wish to get a certificate of attendance from the Frontier of Science seminars, please print out this seminar diary and after the seminar ask the BioCity coordinator to sign it
  • Please note that any audio or video recording of the seminars is strictly forbidden.

 

Start: Thursday, April 27, 2023 at 12:00

End: Thursday, April 27, 2023 at 13:00

Location: PharmaCity Auditorium, Itäinen Pitkäkatu 4B, Turku


Download iCal file Google Calendar Back to listview